
    
      This will be a 5-arm, multicentered, randomized, double-masked, vehicle-controlled study
      conducted in 2 parts.

      Part 1 is the primary treatment period of 3 years, during which participants will receive 1
      of 3 masked medications.

      Part 2 is the randomized withdrawal period of 1 year, during which participants originally
      receiving Vehicle will receive SYD-101, and participants originally receiving SYD-101 will
      receive either Vehicle or SYD-101.
    
  